Vascular Sensitivity to Adrenergic Agonists in Patients With CHF and in Healthy Subjects

Congestive Heart Failure Clinical Trial

Official title:

Effect of Medications on Vascular Response in Patients With CHF and in Healthy Subjects

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00782782
• Other study ID #: 366-28.12.07
• Status: Active, not recruiting
• Phase: N/A
• First received: October 26, 2008
• Last updated: October 28, 2008
• Start date: August 2008
• Est. completion date: December 2011

Study information

• Verified date: October 2008
• Source: Hadassah Medical Organization
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Observational

Clinical Trial Summary

Congestive Heart failure (CHF) is asociated with changes in cardiac function and vascular responses. The aim of this study is to characterize these differences. Our hypothesis is, that there are differences in vascular responses between healthy subjects and patients with CHF.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 80
• Est. completion date: December 2011
• Est. primary completion date: December 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients with congestive heart failure NYHA I-II

• Stable clinical condition

Exclusion Criteria:

• Resting systolic blood pressure < 100

• Resting heart rate < 50

• Hypersensitivity to dexmedetomidine, phenylephrine, isoproterenol, terbutaline

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Congestive Heart Failure
• Heart Failure

Locations

Country	Name	City	State
Israel	Hadassah University Hospital	Jerusalem

Sponsors (1)

Lead Sponsor	Collaborator
Hadassah Medical Organization

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	vascular sensitivity (ED50) and response (Emax) to dexmedetomidine, phenylephrine, isoproterenol and terbutaline		3 weeks	No